mouse anti collagen type ii col2 monoclonal antibody  (Developmental Studies Hybridoma Bank)

Journal: Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society

Article Title: SEQUENTIAL EXPOSURE TO FIBROBLAST GROWTH FACTORS (FGF) 2, 9 AND 18 ENHANCES hMSC CHONDROGENIC DIFFERENTIATION

doi: 10.1016/j.joca.2014.11.013

Figure Lengend Snippet: FGF2-expanded cells were stimulated with ligands or mutant variants for 7 days starting at d14 (until d21). Receptor neutralizing antibodies were added 48 hours in advance (d12) to assure blocking before ligands were administered. Pellet shown in the insert (control) corresponds to black dots shown on B). (A) Histological assessment of representative pellets confirming the results with FGF ligands and mutants (as presented in Fig. 3 – d14), and the determinant role of FGFR3 in this effect, (B) GAG/DNA quantification and gene expression analysis of type 2 collagen and aggrecan, assessed by qRT-PCR performed at day 21. Statistical significance (#) was obtained comparing all values to control pellet (black dots) with the following p values: for GAG/DNA: β+9 (0.0007), β+9v1 (<0.0001), β+9+R1 (0.0004), β+9+R3 (0.0012), β+18 (0.0008), β+18v3 (0.0002), β+18+R1 (0.0091), β+18+R3 (0.0100). For Aggrecan expression: β+9v1 (<0.0013) and β+18v3 (0.0003). For Col2 expression β+9v1 (0.0002), β+18v3 (0.0001), β+18+R1 (0.0009). All other comparisons were p > 0.1. The effects of blocking FGFR1 and FGFR3 receptors when compared with respective growth factor alone are shown in the graph with significant differences (p values) displayed in color. N=4.

Article Snippet: Nonspecific binding sites were blocked with 2.5% normal horse serum, sections were incubated overnight with mouse monoclonal Col2 antibody (CIIC1; Developmental studies hybridoma bank, Iowa City, IA).

Techniques: Mutagenesis, Blocking Assay, Control, Gene Expression, Quantitative RT-PCR, Expressing